MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study
I'm PortAI, I can summarize articles.
MicroPort CardioFlow Medtech Corporation has released one-year follow-up results from the early feasibility study of its AltaValveTM transcatheter mitral valve replacement device. The study involved 30 high-risk patients with severe mitral regurgitation across Europe, the U.S., and Japan. Additionally, the company completed a USD175 million Series D financing round to support global trials and commercialization. MicroPort holds exclusive rights for AltaValveTM in several regions, including Mainland China and Taiwan.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments